Clinical Trials

Breast Neoplasms

NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

48 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT05296746 2026-05-14

RIBOLARIS

1,100 enrolled

Breast Neoplasms

NCT06377852 2026-05-13

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

500 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04055493 2026-05-11

ADAPTcycle

1,684 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07400523 2026-04-28

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

446 enrolled

Breast Neoplasms

NCT04116541 2026-04-24

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Genitourinary

Prostatic Neoplasms

NCT05843253 2026-04-22

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

120 enrolled

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

57 enrolled

Breast Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

86 enrolled

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT02712723 2026-03-11

FELINE

121 enrolled 9 charts

Breast Neoplasms

NCT02780128 2026-03-10

NEPENTHE

Phase 1 Terminated

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Neoplasms, Neuroblastoma

NCT02933736 2026-03-06

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

48 enrolled

Glioblastoma, Meningioma

NCT02645149 2026-02-27

Match Mel

Phase 2 Completed

216 enrolled

Dermatologic

Melanoma

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

30 enrolled

Breast Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

37 enrolled

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

272 enrolled

Breast Cancer Metastatic

NCT03285412 2025-12-22

LEADER

120 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

45 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07195227 2025-10-02

CADILLAC

150 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

162 enrolled

BreastClassical hematology

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03834740 2025-05-30

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Phase EARLY_PHASE1 Completed

27 enrolled 17 charts

Phase EARLY_PHASE1 Recruiting

Brain Neoplasms, Glioblastoma, Glioma

NCT06959979 2025-05-07

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

60 enrolled

Phase 3 Active not recruiting

Medulloblastoma

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Breast Neoplasms

NCT04315233 2025-04-22

CHARGE

Phase 1 Recruiting

34 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

202 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

40 enrolled

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT02632045 2024-12-06

MAINTAIN

Phase 2 Completed

169 enrolled 12 charts

Breast Neoplasms

NCT04657679 2024-11-26

LEANORA

Phase 4 Terminated

21 enrolled 19 charts

Breast Neoplasms

NCT06587789 2024-11-21

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

Recruiting

286 enrolled